Cell-cycle effects of the antirheumatic agent cph82
1994 (English)In: British Journal of Rheumatology, ISSN 0263-7103, Vol. 33, no 4, 327-331 p.Article in journal (Refereed) Published
The benzylidated podophyllotoxin glycoside CPH82, a potentially useful drug for treatment of RA, was tested in vitro on nine human haematopoietic cell lines for cell kinetic effects. Previous studies have shown CPH82 to behave like a colchinetype ‘metaphase’ blocker.The distribution of cells within different cell cycle compartments (G1, S, G2 and M) was analysed by a novel method using dual parameter flow cytometric analysis of stage specific antigens (proliferating cell nuclear antigen and Ki-67). With CPH82 concentrations chosen to mimic clinical conditions, eight out of nine lines showed an accumulation of cells in the G2 phase of the cell cycle. In many lines a delayed progress through S seemed to occur. Three lines were blocked in both G1 and G2, whereas the major effect on one line (HL-60) was an accumulation of cells in the G1 phase. Progression of M cells seemed only slightly delayed for some cell lines. In comparison with two related ‘metaphase’ blocking agents (podophyllotoxin and taxol), CPH82 had a different and dose-dependent pattern of cell cycle retardation. It is speculated that the cell kinetic action of CPH82 might give insight into the question why it, unlike other ‘metaphase’ blockers, has proved valuable in the treatment of RA.
Place, publisher, year, edition, pages
1994. Vol. 33, no 4, 327-331 p.
Microtubule antagonist, Cell cycle analysis, Podophyllotoxin, Taxol, Proliferating cell nuclear antigen, Ki-67, Flow cytometry
Rheumatology and Autoimmunity
IdentifiersURN: urn:nbn:se:umu:diva-39192DOI: 10.1093/rheumatology/33.4.327OAI: oai:DiVA.org:umu-39192DiVA: diva2:388797